Arbutus Biopharma Price Target & Analyst Ratings (NASDAQ:ABUS)

$1.65
+0.05 (+3.13 %)
(As of 09/22/2019 04:00 PM ET)
Today's Range
$1.61
Now: $1.65
$1.70
50-Day Range
$1.31
MA: $1.53
$1.79
52-Week Range
$1.29
Now: $1.65
$10.00
Volume274,839 shs
Average Volume161,089 shs
Market Capitalization$93.80 million
P/E RatioN/A
Dividend YieldN/A
Beta1.65

Analyst Ratings

Arbutus Biopharma (NASDAQ:ABUS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
5 Wall Street analysts have issued ratings and price targets for Arbutus Biopharma in the last 12 months. Their average twelve-month price target is $6.3333, suggesting that the stock has a possible upside of 283.84%. The high price target for ABUS is $9.00 and the low price target for ABUS is $5.00. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.402.402.402.40
Ratings Breakdown: 0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
3 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $6.3333$6.3333$6.8333$6.8333
Price Target Upside: 283.84% upside163.89% upside82.22% upside82.22% upside

Arbutus Biopharma (NASDAQ:ABUS) Consensus Price Target History

Arbutus Biopharma (NASDAQ:ABUS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
7/16/2019Chardan CapitalReiterated RatingBuy$5.00High
3/11/2019Echelon Wealth PartnersReiterated RatingHoldMedium
10/16/2018B. RileyUpgradeNeutral ➝ Buy$11.50 ➝ $9.00High
10/15/2018WedbushUpgradeUnderperform ➝ Neutral$5.00Medium
10/9/2018JMP SecuritiesDowngradeMarket PerformHigh
11/7/2017Leerink SwannReiterated RatingMarket Perform$4.00 ➝ $5.00N/A
(Data available from 9/22/2017 forward)
This page was last updated on 9/22/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel